Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma

被引:15
作者
El-Zeftawy, H
Heiba, SI
Jana, S
Rosen, G
Salem, S
Santiago, JF
Abdel-Dayem, HM
机构
[1] New York Med Coll, Dept Radiol, Nucl Med Sect, St Vincents Catholic Med Ctr New York, Valhalla, NY 10595 USA
[2] St Vincents Comprehens Canc Ctr, Dept Med, Sect Med Oncol, New York, NY USA
关键词
D O I
10.1089/108497801750096005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim of the study: To assess the impact of repeated F-18 FDG studies on the management of patients with bone and soft tissue (B&S) sarcomas. Material and Methods: Twenty patients with B&S tissue tumors (11 M and 9 F age 17-72 years) had 52 F-18 FDG Dual Head Coincidence Imaging (DHCI) studies. 7 patients were followed for 6 months to 2 years clinically after removal of the primary tumor. Thirteen patients were evaluated for suspected recurrences. Patient's preparation, F-18 FDG injection and imaging procedure were done according to department protocol. Attenuation corrected images were interpreted visually by 3 trained physicians. Tumor to background ratios were calculated for all lesions. Results: In 13 patients having both studies, baseline FDG and CT/MRI were concordant in 8 patients, FDG defected more lesions in 3 patients but it did not detect 4 metastatic pulmonary nodules in 2 patients. Follow up studies showed stable disease in 10 patients while 6 patients who showed worsening disease needed to change their chemotherapy. Surgery was avoided in 2 patients and 2 patients showed improved response. Conclusion: Repeated F-18 FDG DHCI examinations proved to have an impact on the clinical management of patients with malignant bone and soft tissue sarcoma. It helps to differentiate postoperative changes from local recurrence.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 29 条
  • [1] The role of nuclear medicine in primary bone and soft tissue tumors
    AbdelDayem, HM
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1997, 27 (04) : 355 - 363
  • [2] ADLER LP, 1991, J NUCL MED, V32, P1508
  • [3] [Anonymous], SEER cancer statistics review, 1975-2001
  • [4] BEDER H, 1997, ANTICANCER RES, V17, P1687
  • [5] COINDRE JM, 1996, J NUCL MED, V37, P257
  • [6] COLEMAN RE, 1991, CANCER, V67, P1261
  • [7] EVALUATION OF TUMOR METABOLISM AND MULTIDRUG-RESISTANCE IN PATIENTS WITH TREATED MALIGNANT-LYMPHOMAS
    DIMITRAKOPOULOUSTRAUSS, A
    STRAUSS, LG
    GOLDSCHMIDT, H
    LORENZ, WJ
    MAIERBORST, W
    VANKAICK, G
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (05): : 434 - 442
  • [8] ENZINGER FM, 1988, SOFT TISSUE TUMORS
  • [9] ENZINGER FM, 1995, SOFT TISSUE TUMORS, P1
  • [10] Garcia JR, 1996, J NUCL MED, V37, P1476